Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice

被引:250
作者
Motto, DG
Chauhan, AK
Zhu, GJ
Homeister, J
Lamb, CB
Desch, KC
Zhang, WR
Tsai, HM
Wagner, DD
Ginsburg, D
机构
[1] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA
[2] CBR, Inst Biomed Res, Boston, MA USA
[3] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA
[4] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA
[6] Albert Einstein Coll Med, Dept Internal Med, New York, NY USA
[7] Univ Michigan, Dept Internal Med, Ann Arbor, MI USA
[8] Howard Hughes Med Inst, Chevy Chase, MD USA
[9] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA
关键词
D O I
10.1172/JCI26007
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness caused by deficiency of the vWF-cleaving protease ADAMTS13. Here we show that ADAMTS13-deficient mice are viable and exhibit normal survival, although vWF-mediated platelet-endothelial interactions are significantly prolonged. Introduction of the genetic background CASA/Rk (a mouse strain with elevated plasma vWF) resulted in the appearance of spontaneous thrombocytopenia in a subset of ADAMTS13-deficient mice and significantly decreased survival. Challenge of these mice with shigatoxin (derived from bacterial pathogens associated with the related human disease hemolytic uremic syndrome) resulted in a striking syndrome closely resembling human TTP. Surprisingly, no correlation was observed between plasma vWF level and severity of TTP, implying the existence of TTP-modifying genes distinct from vWF. These data suggest that microbe-derived toxins (or possibly other sources of endothelial injury), together with additional genetic susceptibility factors, are required to trigger TTP in the setting of ADAMTS13 deficiency.
引用
收藏
页码:2752 / 2761
页数:10
相关论文
共 37 条
[31]   LATE RELAPSES IN PATIENTS SUCCESSFULLY TREATED FOR THROMBOTIC THROMBOCYTOPENIC PURPURA [J].
SHUMAK, KH ;
ROCK, GA ;
NAIR, RC ;
ADAMS, G ;
BENNY, B ;
BUSKARD, NA ;
CAPLAN, S ;
CARD, R ;
CLARK, WF ;
FORD, P ;
FREEDMAN, J ;
GORDON, P ;
GORELICK, M ;
KELTON, J ;
KLASSEN, J ;
LEBLOND, P ;
LEPINEMARTIN, M ;
MCBRIDE, J ;
MONTE, M ;
RAYNER, H ;
SHORE, T ;
STERNBACH, M ;
SUTTON, DMC ;
JONES, JV .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (08) :569-572
[32]   Genetic dissection of complex traits with chromosome substitution strains of mice [J].
Singer, JB ;
Hill, AE ;
Burrage, L ;
Olszens, KR ;
Song, JH ;
Justice, M ;
O'Brien, WE ;
Conti, DV ;
Witte, JS ;
Lander, ES ;
Nadeau, JH .
SCIENCE, 2004, 304 (5669) :445-448
[33]   INDUCIBLE SECRETION OF LARGE, BIOLOGICALLY POTENT VONWILLEBRAND-FACTOR MULTIMERS [J].
SPORN, LA ;
MARDER, VJ ;
WAGNER, DD .
CELL, 1986, 46 (02) :185-190
[34]   Familial acquired thrombotic thrombocytopenic purpura:: ADAMTS13 inhibitory autoantibodies in identical twins [J].
Studt, JD ;
Hovinga, JAK ;
Radonic, R ;
Gasparovic, V ;
Ivanovic, D ;
Merkler, M ;
Wirthmueller, U ;
Dahinden, C ;
Furlan, M ;
Lämmle, B .
BLOOD, 2004, 103 (11) :4195-4197
[35]   Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura [J].
Tsai, HM ;
Lian, ECY .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1585-1594
[36]   Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) [J].
Veyradier, A ;
Lavergne, JM ;
Ribba, AS ;
Obert, B ;
Loirat, C ;
Meyer, D ;
Girma, JP .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (03) :424-429
[37]   High incidence of malaria in alpha-thalassaemic children [J].
Williams, TN ;
Maitland, K ;
Bennett, S ;
Ganczakowski, M ;
Peto, TEA ;
Newbold, CI ;
Bowden, DK ;
Weatherall, DJ ;
Clegg, JB .
NATURE, 1996, 383 (6600) :522-525